NDAORAL-21TABLET
Approved
May 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 2-21 is an oral contraceptive combining mestranol (estrogen) and norethindrone (progestin) in a 21-day tablet regimen. It prevents ovulation and thickens cervical mucus to provide contraceptive efficacy. This is a foundational hormonal contraceptive approved over 60 years ago.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on lifecycle extension or managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 2-21 offers minimal career growth potential due to the product's legacy status and approaching loss of exclusivity. Positions are primarily maintenance-focused, supporting existing patient populations and managed care negotiations rather than building market presence.
Brand ManagerProduct Manager
Worked on ORTHO-NOVUM 2-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.